7Baggers
 Chardan Capital Raises Price Target on Passage Bio (PASG) to $21  GuruFocus Wed, 12 Nov 2025 13:10:31 GMT
 PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates  Nasdaq Tue, 11 Nov 2025 02:00:00 GMT
 Passage Bio Cuts Losses And Gains Analysts’ Confidence  Finimize Mon, 10 Nov 2025 23:02:08 GMT
 Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu  GuruFocus Mon, 10 Nov 2025 22:35:23 GMT
 Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)  TipRanks Mon, 10 Nov 2025 22:24:04 GMT
 Passage Bio Reports Q3 Financial Results and Updates  TipRanks Mon, 10 Nov 2025 22:13:51 GMT
 Passage Bio Q3 net loss narrows to $7.7 mln  MarketScreener Mon, 10 Nov 2025 21:27:39 GMT

Passage Bio, Inc
(NASDAQ:PASG) 

PASG stock logo

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid b...

Founded: 2017
Full Time Employees: 20
CEO: Bruce A. Goldsmith  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends